ZA884237B - Doxazosin as an anti-atherosclerosis agent - Google Patents
Doxazosin as an anti-atherosclerosis agentInfo
- Publication number
- ZA884237B ZA884237B ZA884237A ZA884237A ZA884237B ZA 884237 B ZA884237 B ZA 884237B ZA 884237 A ZA884237 A ZA 884237A ZA 884237 A ZA884237 A ZA 884237A ZA 884237 B ZA884237 B ZA 884237B
- Authority
- ZA
- South Africa
- Prior art keywords
- doxazosin
- atherosclerosis
- retarding
- agent
- reducing
- Prior art date
Links
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001389 doxazosin Drugs 0.000 title abstract 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 2
- 230000000979 retarding effect Effects 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/089,716 US4758569A (en) | 1987-08-26 | 1987-08-26 | Doxazosin as an anti-atherosclerosis agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA884237B true ZA884237B (en) | 1990-02-28 |
Family
ID=22219243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA884237A ZA884237B (en) | 1987-08-26 | 1988-06-14 | Doxazosin as an anti-atherosclerosis agent |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4758569A (cs) |
| EP (1) | EP0305028B1 (cs) |
| JP (1) | JPS6471817A (cs) |
| KR (1) | KR910002145B1 (cs) |
| AT (1) | ATE77552T1 (cs) |
| AU (1) | AU594880B2 (cs) |
| CA (1) | CA1323572C (cs) |
| DE (1) | DE3872333T2 (cs) |
| DK (1) | DK170499B1 (cs) |
| HU (1) | HU204196B (cs) |
| IE (1) | IE60005B1 (cs) |
| IL (1) | IL86735A (cs) |
| MY (1) | MY103102A (cs) |
| NZ (1) | NZ225053A (cs) |
| ZA (1) | ZA884237B (cs) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
| US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
| US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| ATE187069T1 (de) * | 1992-04-01 | 1999-12-15 | Pfizer | Hydroxylierte metaboliten und derivate von doxazosin gegen atherosklerose |
| US5449679A (en) * | 1994-07-29 | 1995-09-12 | Leonard; Robert J. | Process and products for reducing biological fluid levels of a lipid soluble waste |
| IL120303A0 (en) * | 1996-03-27 | 1997-06-10 | Pfizer | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer |
| US6177430B1 (en) | 1997-03-27 | 2001-01-23 | Pfizer Inc | Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia |
| EP1150669A4 (en) * | 1999-02-05 | 2005-06-22 | Angiogenix Inc | FORMULATIONS ON L-ARGININE BASE FOR DISEASE TREATMENT AND USE THEREOF |
| IL153633A0 (en) | 2000-07-13 | 2003-07-06 | Takeda Chemical Insustries Ltd | Lipid-rich plaque inhibitors |
| US20040019096A1 (en) * | 2001-10-23 | 2004-01-29 | Vlassios Andronis | Novel formulations of carvedilol |
| KR100462304B1 (ko) * | 2002-07-30 | 2004-12-17 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR100538641B1 (ko) * | 2002-07-30 | 2005-12-22 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR100496436B1 (ko) * | 2002-07-30 | 2005-06-20 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| KR100467669B1 (ko) | 2002-08-21 | 2005-01-24 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| CN100394989C (zh) | 2002-11-15 | 2008-06-18 | 华沙整形外科股份有限公司 | 包含微粒状基于胶原材料的组合物的制药应用和包含所述组合物的滑膜关节 |
| US8399619B2 (en) | 2006-06-30 | 2013-03-19 | Warsaw Orthopedic, Inc. | Injectable collagen material |
| US8118779B2 (en) | 2006-06-30 | 2012-02-21 | Warsaw Orthopedic, Inc. | Collagen delivery device |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4130647A (en) * | 1977-07-08 | 1978-12-19 | Pfizer Inc. | Methods for treating congestive heart failure and ischemic heart disease |
| US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
| US4361564A (en) * | 1978-11-30 | 1982-11-30 | Edwards K David G | Renoprotective treatments employing vasodilator compounds |
| US4532135A (en) * | 1981-02-09 | 1985-07-30 | Edwards K David G | Renoprotective treatments employing vasodilator compounds |
| US4582832A (en) * | 1984-10-09 | 1986-04-15 | Pfizer Inc. | Trimazosin as an anti-atherosclerosis agent |
-
1987
- 1987-08-26 US US07/089,716 patent/US4758569A/en not_active Expired - Lifetime
-
1988
- 1988-06-03 EP EP88305069A patent/EP0305028B1/en not_active Expired - Lifetime
- 1988-06-03 AT AT88305069T patent/ATE77552T1/de not_active IP Right Cessation
- 1988-06-03 DE DE8888305069T patent/DE3872333T2/de not_active Expired - Lifetime
- 1988-06-07 IE IE169588A patent/IE60005B1/en not_active IP Right Cessation
- 1988-06-09 AU AU17529/88A patent/AU594880B2/en not_active Expired
- 1988-06-09 DK DK313688A patent/DK170499B1/da not_active IP Right Cessation
- 1988-06-14 IL IL8673588A patent/IL86735A/en not_active IP Right Cessation
- 1988-06-14 ZA ZA884237A patent/ZA884237B/xx unknown
- 1988-06-15 MY MYPI88000660A patent/MY103102A/en unknown
- 1988-06-16 NZ NZ225053A patent/NZ225053A/en unknown
- 1988-06-20 HU HU883139A patent/HU204196B/hu unknown
- 1988-07-30 KR KR1019880009761A patent/KR910002145B1/ko not_active Expired
- 1988-08-23 CA CA000575443A patent/CA1323572C/en not_active Expired - Lifetime
- 1988-08-23 JP JP63209329A patent/JPS6471817A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IL86735A (en) | 1994-05-30 |
| IL86735A0 (en) | 1988-11-30 |
| DE3872333T2 (de) | 1992-12-03 |
| US4758569A (en) | 1988-07-19 |
| AU594880B2 (en) | 1990-03-15 |
| EP0305028A3 (en) | 1990-03-14 |
| EP0305028B1 (en) | 1992-06-24 |
| EP0305028A2 (en) | 1989-03-01 |
| KR890003379A (ko) | 1989-04-14 |
| HUT51141A (en) | 1990-04-28 |
| NZ225053A (en) | 1997-02-24 |
| IE60005B1 (en) | 1994-05-18 |
| MY103102A (en) | 1993-04-30 |
| AU1752988A (en) | 1989-03-02 |
| DK313688D0 (da) | 1988-06-09 |
| IE881695L (en) | 1989-02-26 |
| JPS6471817A (en) | 1989-03-16 |
| DK313688A (da) | 1989-02-27 |
| HU204196B (en) | 1991-12-30 |
| DE3872333D1 (de) | 1992-07-30 |
| CA1323572C (en) | 1993-10-26 |
| JPH0575729B2 (cs) | 1993-10-21 |
| ATE77552T1 (de) | 1992-07-15 |
| DK170499B1 (da) | 1995-10-02 |
| KR910002145B1 (ko) | 1991-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA884237B (en) | Doxazosin as an anti-atherosclerosis agent | |
| GB2240475B (en) | 5 ht-3 antagonist for the prevention or reduction of dependence | |
| GB8714865D0 (en) | Photopolymerizable composition iii | |
| EP0304556A3 (en) | High availability multiprocessing | |
| GB2211940B (en) | Measuring the roundness of object | |
| EP0275970A3 (en) | Positive-working photoresist composition | |
| GB8801765D0 (en) | Potassium clavulanate | |
| GB8705302D0 (en) | Combined scale & interferometer | |
| GB2201716B (en) | Collapsible builders' staging | |
| ZA843224B (en) | Substituted cephalosporins as anti-inflammatory and antidegenerative agents | |
| EP0294785A3 (en) | Magenta dye-forming coupler | |
| ZA932307B (en) | Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents | |
| GB2143234B (en) | (oxoheterocyclic carbonamido) cephem carboxylic acid derivatives | |
| GB8806073D0 (en) | 4-benzylthiophene(or furan)-2-sulfonamides as antiglaucoma agents | |
| AU577781B2 (en) | Lung imaging with radiolabelled agents | |
| GB8704928D0 (en) | Collapsible builders' staging | |
| IE870349L (en) | 3-alkoxy-2-aminopropylamines useful as cardiovascular agents | |
| GB8313633D0 (en) | Disodium salicylate as nucleating agent | |
| IE873403L (en) | Anxiolytic-n-(1-azabicyclo £2,2,2| oct-3-yl) benzamides and¹thiobenzamides | |
| GB8707808D0 (en) | Inspection of composite structures | |
| GB8311085D0 (en) | Toolmakers' squares | |
| IE872144L (en) | Process for the preparation of antibacterial¹7-oxo-4-thia-1-azabicyclo £3.2.0| hept-2-ene derivatives | |
| PL249918A1 (en) | Method of obtaining pharmaceutically useful benzothiasine dioxide | |
| GB8702925D0 (en) | Bearing structures | |
| ZA88583B (en) | Potassium clavulanate |